Dechert Guides Zealand Pharma's Upsized $78M IPO
Danish biotechnology firm Zealand Pharma, a venture capital-backed developer of diabetes treatments, raised $78 million in an enlarged initial public offering that priced late Wednesday, under guidance from Dechert LLP....To view the full article, register now.
Already a subscriber? Click here to view full article